Corneal injuries are a leading cause of vision impairment, yet current therapies provide limited benefit due to poor ocular bioavailability and rapid drug clearance. To address this challenge, we developed a pH-sensitive in situ gel of p-coumaric acid (pCA) for sustained ocular delivery and enhanced wound healing. In vitro studies on SIRC cells identified 80 μg/mL pCA as a safe and effective concentration for supporting viability and migration. The optimized gel, formulated with Carbopol 940 and HPMC K100 M using central composite design, exhibited rapid gelation at ocular pH, pseudoplastic rheology, suitable zeta potential, and high entrapment efficiency (85.95%). FESEM confirmed pH-triggered sol–gel transition, while in vitro release demonstrated sustained delivery for 12 h (92.62% cumulative release). Safety was verified through RBC lysis, CAM, goat corneal histology, and rabbit eye irritation tests, all showing no adverse effects. In vivo evaluation in a rat corneal alkali burn model confirmed accelerated wound healing. This system offers a safe, biocompatible, and effective ocular therapy for corneal wounds.
Building similarity graph...
Analyzing shared references across papers
Loading...
Subramanyam Polopalli
Achintya Saha
Pakter Niri
Molecular Pharmaceutics
University of Calcutta
Dibrugarh University
Defence Research and Development Organisation
Building similarity graph...
Analyzing shared references across papers
Loading...
Polopalli et al. (Mon,) studied this question.
www.synapsesocial.com/papers/69ba428e4e9516ffd37a2e51 — DOI: https://doi.org/10.1021/acs.molpharmaceut.5c01490